Wells Fargo & Company Boosts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $23.00

Bicara Therapeutics (NASDAQ:BCAX) had its target price lifted by equities researchers at Wells Fargo & Company from $16.00 to $23.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target points to a potential downside of 3.20% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. BTIG Research upped their target price on Bicara Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. The Goldman Sachs Group restated a “neutral” rating on shares of Bicara Therapeutics in a research report on Wednesday. Finally, Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.09.

Bicara Therapeutics Trading Down 14.3%

Bicara Therapeutics stock opened at $23.76 on Wednesday. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -8.55 and a beta of -0.75. The stock’s 50 day moving average is $25.90 and its 200-day moving average is $21.69. Bicara Therapeutics has a 12 month low of $9.67 and a 12 month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, meeting the consensus estimate of ($0.82). As a group, equities research analysts predict that Bicara Therapeutics will post -3.42 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Claire Mazumdar sold 10,000 shares of the company’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $28.42, for a total value of $284,200.00. Following the sale, the chief executive officer owned 362,152 shares in the company, valued at $10,292,359.84. This represents a 2.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total value of $817,641.72. Following the transaction, the chief operating officer owned 182,177 shares of the company’s stock, valued at $5,279,489.46. This trade represents a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 88,450 shares of company stock worth $2,366,675 over the last three months. 13.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bicara Therapeutics

Several large investors have recently bought and sold shares of BCAX. Deutsche Bank AG lifted its holdings in Bicara Therapeutics by 0.9% during the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after acquiring an additional 1,171 shares during the period. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the period. Mariner LLC increased its position in shares of Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after purchasing an additional 1,902 shares during the last quarter. Invesco Ltd. increased its position in shares of Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after purchasing an additional 1,962 shares during the last quarter. Finally, Quantinno Capital Management LP raised its stake in shares of Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after purchasing an additional 2,447 shares during the period.

Key Stories Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: BTIG raises price target: BTIG Research increased its price target for Bicara from $28 to $39 and upgraded the stock to “buy,” implying substantial upside from recent trading levels. Benzinga report
• Positive Sentiment: Pivotal cancer trial remains on schedule: Wedbush said Bicara’s cancer study is on track to complete enrollment in 2026, supporting the company’s near-term clinical-development outlook. Wedbush cancer study report
• Positive Sentiment: Clinical progress highlighted: Bicara reported second-quarter progress, including advances in pivotal-trial enrollment. The update previously helped drive gains in the stock and reinforces expectations that the company is progressing toward important clinical milestones. Yahoo Finance trial-enrollment report
• Neutral Sentiment: Quarterly loss matched expectations: Bicara reported a second-quarter loss of $0.82 per share, in line with the analyst consensus estimate. The result provided no earnings surprise, while the company remains unprofitable and analysts expect a full-year loss. Bicara earnings report
• Negative Sentiment: Leadership transition adds execution uncertainty: Bicara announced strategic leadership changes as it moves into its next phase of execution and growth. Although management characterized the changes as part of the company’s evolution, investors may view the transition as an added risk while pivotal-trial execution remains central to the valuation. Bicara quarterly update and leadership transition

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.